HEPATIQ™ LLC is an early stage company focused on diagnosing the severity of liver disease.  Chronic liver disease (CLD) is a slow and silent killer.  It is widespread with about 15% prevalence. About 32,000 people die each year in the US from liver disease.

Our HEPATIQ™ software provides a precise index of liver disease severity.  
The HEPATIQ™ technology automates the Quantitative Liver Spleen Scan (QLSS™) that has been proven to be an accurate predictor of clinical outcomes in the recently concluded HALT-C trial.
The HEPATIQ Software has been cleared by the Food and Drug Administration for sale in the U.S.A.

For more information, please contact:


Dipu Ghosh, MSEE, MBA.
Co-Founder & Chief Executive Officer


John Hoefs, MD.
Co-Founder & Chief Operating Officer